Hydrogen sulfide delivery system and construction method and application thereof
By constructing a hydrogen sulfide delivery system of hyaluronic acid and nitroimidazole, the precise delivery of hydrogen sulfide to the tumor hypoxic zone is achieved, the problem of systemic toxicity and narrow time window of hydrogen sulfide in the existing technology is solved, and the tumor blood vessels are improved Normalization effects and treatment sensitivity.
Patent Information
- Application Number
- CN202411039777.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-19
AI Technical Summary
In the prior art, hydrogen sulfide is used to regulate tumor vascular normalization, and there are problems such as systemic antivascular toxicity, narrow time window for vascular normalization, and unclear regulatory mechanisms, making it difficult to achieve precise regulation and long-term sustained release.
Constructing a hydrogen sulfide delivery system based on hyaluronic acid and nitroimidazole, 2-nitroimidazole is grafted onto hyaluronic acid through Hoffman alkylation reaction and detert-butoxycarbonyl reaction, and is then grafted onto hyaluronic acid by emulsion diffusion method Prepare a hydrogen sulfide-loaded donor to achieve accurate delivery of hydrogen sulfide to the tumor hypoxic zone and regulate tumor blood vessel normalization.
It effectively reduces systemic toxicity, extends the time window for vascular normalization, improves the enrichment of hydrogen sulfide in tumors, enhances the sensitivity of chemotherapy and immunotherapy, and provides a more favorable therapeutic environment.
Smart Images

Figure CN118978617A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biopharmaceutical technology, and in particular to a hydrogen sulfide delivery system and a construction method and application thereof. Background Art
[0002] The imbalance between pro-angiogenesis and anti-angiogenesis in tumors leads to abnormal tumor vascular function, which in turn forms a tumor microenvironment such as hypoxia and immunosuppression, which is a key factor in the poor efficacy of chemotherapy and immunotherapy. Studies have shown that low-dose anti-angiogenic drugs can regulate this balance, normalize tumor blood vessels, reshape the tumor microenvironment, and effectively improve the sensitivity of chemotherapy and immunotherapy. The results of the FUTURE series of studies on triple-negative breast cancer (TNBC) conducted by Professor Shao Zhimin's team at the Affiliated Cancer Hospital of Fudan University showed that low-dose anti-angiogenesis combined with immunotherapy has increased the median PFS of more than 50% of TNBC patients to 8.2 months, which is much better than the 1.7-5.6 months of chemotherapy. However, this type of drug has a narrow time window for vascular normalization and requires long-term use, leading to systemic anti-angiogenic toxicity, such as venous thrombosis and hypertension. Therefore, there is an urgent need to develop drugs and strategies that precisely regulate tumor vascular normalization.
[0003] H2S is the third gaseous signal transduction substance discovered after NO and CO, and has been shown to regulate angiogenesis, immune cell infiltration and other functions, all of which are related to the regulation of tumor vascular normalization. Although H2S can be used to regulate tumor vascular normalization, there are still some problems that need to be solved: (1) How to reduce the systemic anti-angiogenic toxicity of H2S and prolong the vascular normalization window; (2) The laws and mechanisms of H2S regulation of the balance between anti-angiogenesis and pro-angiogenesis still need to be further explored; (3) Can prolonging the tumor vascular normalization time window affect tumor progression and metastasis? Therefore, constructing a tumor-targeted H2S precision delivery system and exploring its regulation laws and mechanisms of action on tumor vascular normalization is expected to reduce systemic anti-angiogenic toxicity, prolong the vascular normalization time window, and enhance the effects of tumor chemotherapy and immunotherapy, which is not only of great scientific significance, but also has broad clinical application prospects. Summary of the invention
[0004] The purpose of the present invention is to provide a hydrogen sulfide delivery system and its construction method and application based on the current situation that the existing technology lacks accurate delivery of hydrogen sulfide.
[0005] The purpose of the present invention can be achieved by the following technical solutions:
[0006] One of the technical solutions of the present invention is to provide a method for constructing a hydrogen sulfide delivery system, comprising the following steps:
[0007] S1, dissolving 2-nitroimidazole in N,N-dimethylformamide, then adding potassium carbonate and N-(tert-butoxycarbonyl-amino)-bromohexane to react, to obtain 2-(2-nitro-1H-imidazole)hexylamine protected by a Boc group (t-Butyloxy carbonyl, tert-butoxycarbonyl);
[0008] S2, dissolving the 2-(2-nitro-1H-imidazole)hexylamine obtained in step S1 in dichloromethane, and then adding trifluoroacetic acid to react to remove the Boc group to obtain 2-(2-nitro-1H-imidazole)hexylamine;
[0009] S3, adding 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide to the hyaluronic acid aqueous solution to react and activate the carboxyl groups on the hyaluronic acid, and then adding 2-(2-nitro-1H-imidazole)hexylamine obtained in step S2 to react and obtain a hyaluronic acid-nitroimidazole delivery system;
[0010] S4, dispersing the hydrogen sulfide donor in dimethyl sulfoxide as an organic phase and dripping it into the stirred aqueous solution of the hyaluronic acid-nitroimidazole delivery system obtained in step S3, and then dripping it into stirred water to obtain a hydrogen sulfide delivery system.
[0011] In some specific embodiments, in step S1, the molar ratio of 2-nitroimidazole, potassium carbonate, and N-(tert-butoxycarbonyl-amino)-bromohexane is 1:2:1.
[0012] In some specific embodiments, in step S1, in the reaction, the reaction temperature is 80-85° C., and the reaction is stirred for 8-12 hours.
[0013] In some specific embodiments, in step S1, after the reaction is completed, the organic layer is extracted with distilled water and ethyl acetate, collected, and dried and evaporated to obtain 2-(2-nitro-1H-imidazole)hexylamine protected by a Boc group.
[0014] In some specific embodiments, in step S2, the concentration of 2-(2-nitro-1H-imidazole)hexylamine in dichloromethane is 80 mg / mL, and the volume ratio of dichloromethane to trifluoroacetic acid is 2:1.
[0015] In some specific embodiments, in step S2, the reaction temperature is 20-25° C., and the reaction is stirred for 3-6 hours.
[0016] In some specific embodiments, in step S2, after the reaction is completed, the solution is adjusted to be alkaline with saturated sodium bicarbonate, extracted with distilled water and ethyl acetate, and the organic layer is collected and dried and evaporated to obtain 2-(2-nitro-1H-imidazole)hexylamine.
[0017] In some specific embodiments, in step S3, the concentration of hyaluronic acid in the hyaluronic acid aqueous solution is 20 mg / mL; the molar ratio of hyaluronic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, N-hydroxysuccinimide, and 2-(2-nitro-1H-imidazole)hexylamine is 1:4:4:2.
[0018] In some specific embodiments, in step S3, the conditions for adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide to react are: stirring at 0-5° C. for 1-2 hours;
[0019] The reaction conditions for adding 2-(2-nitro-1H-imidazole)hexylamine obtained in step S2 are: stirring at 20-25° C. for 12-24 hours.
[0020] In some specific embodiments, in step S3, after the reaction is completed, the hyaluronic acid-nitroimidazole delivery system is obtained by dialyzing in distilled water for 24 to 48 hours and then freeze-drying.
[0021] In some specific embodiments, in step S3, the freeze-drying conditions are: vacuum degree of 1 Pa, temperature of -70 to -50°C, and time of 48 to 96 hours.
[0022] In some specific embodiments, in step S4, the concentration of the hyaluronic acid-nitroimidazole delivery system aqueous solution is 1-25 mg / mL, the mass ratio of the hydrogen sulfide donor to the hyaluronic acid-nitroimidazole delivery system is 1:10, and the volume ratio of dimethyl sulfoxide to water is 1:4.
[0023] In some specific embodiments, in step S4, the flow rate of dripping into the hyaluronic acid-nitroimidazole delivery system aqueous solution is 1-10 mL / h, the flow rate of dripping into water is 4-6 mL / h, and stirring is carried out at 20-25°C for 12-24 hours.
[0024] In some specific embodiments, in step S4, after the dropwise addition is completed, the mixture is dialyzed in distilled water and then freeze-dried to obtain the hydrogen sulfide delivery system.
[0025] In some specific embodiments, in step S4, the dialysis uses a dialysis bag with a dialysis molecular weight of 2000Da.
[0026] In some specific embodiments, in step S4, the freeze-drying conditions are: vacuum degree of 1 Pa, temperature of -70 to -50°C, and time of 48 to 96 hours.
[0027] The second technical solution of the present invention is to provide a hydrogen sulfide delivery system, which is obtained based on the construction method described in one of the above technical solutions.
[0028] A third technical solution of the present invention is to provide an application of the hydrogen sulfide delivery system as described in the second technical solution above, wherein the hydrogen sulfide delivery system is used for preparing drugs for regulating normalization of tumor blood vessels.
[0029] The hydrogen sulfide used in the present invention has the property of regulating vascular normalization when it is enriched in the hypoxic area of the tumor, but it is concentration-dependent in regulating the balance of pro- and anti-tumor angiogenesis and immune cell infiltration. Therefore, selecting a long-acting sustained-release H2S donor and delivering it precisely is the key to reducing systemic toxicity and extending the time window for tumor vascular normalization.
[0030] The hyaluronic acid used in the present invention is a high molecular weight polysaccharide widely present in the human body. It is a safe biomacromolecule that targets the CD44 receptor of tumor cells and has good biocompatibility and targeting; nitroimidazole is a hypoxia responsive group. Therefore, the present invention first converts 2-nitroimidazole into 2-(2-nitro-1H-imidazole)hexylamine through Hofmann alkylation reaction and de-tert-butyloxycarbonylation reaction, grafts it onto hyaluronic acid through amide synthesis reaction, and then prepares the loaded hydrogen sulfide donor through emulsion diffusion method to generate a hydrogen sulfide precision delivery system, so as to achieve the precise delivery of hydrogen sulfide to the hypoxic area of the tumor and regulate the normalization of tumor blood vessels.
[0031] The mechanism of action of the hydrogen sulfide delivery system prepared by the present invention in vivo is:
[0032] The hydrogen sulfide delivery system effectively enriches in tumors by targeting the CD44 receptor of tumor cells; the nitroimidazole hypoxia response group undergoes a redox reaction to generate an aminoimidazole group, which converts from a hydrophobic group to a hydrophilic group, thereby causing the hyaluronic acid-nitroimidazole delivery system to rupture and release a hydrogen sulfide donor. Through the highly expressed enzyme reaction in the tumor microenvironment, the release of hydrogen sulfide in the hypoxic area of the tumor is achieved, and the normalization of tumor blood vessels is regulated. Therefore, this method can effectively increase the enrichment of hydrogen sulfide in tumors, avoid damage to healthy tissues, and provide a more favorable treatment environment for chemotherapy, immunotherapy, etc. It has broad application prospects in targeted delivery and improved treatment of tumors.
[0033] Compared with the prior art, the present invention has the following beneficial effects:
[0034] (1) The preparation method provided by the present invention is simple and mild. The prepared hydrogen sulfide delivery system is spherical and has the advantages of small particle size, negative surface charge, good stability, etc. It can realize the controlled release of drugs in the hypoxic part of the tumor, but will not be released in other parts. It will not cause damage to normal tissues during the delivery process, thus achieving precise tumor targeting.
[0035] (2) The hydrogen sulfide delivery system provided by the present invention combines the hypoxic delivery characteristics of the hyaluronic acid-nitroimidazole delivery system with the characteristics of the hydrogen sulfide donor in regulating vascular normalization, so that hydrogen sulfide can be effectively enriched in the hypoxic area of the tumor, thereby achieving the regulation of tumor vascular normalization and providing a favorable environment for tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 These are the TEM (a), DLS (b), Zeta potential (c), UV-vis (d), FT-IR (e), and stability (f) characterization spectra of the hydrogen sulfide precision delivery system prepared in Example 1.
[0037] Figure 2 This is the ultraviolet absorption spectrum of the hypoxia response of the hydrogen sulfide precision delivery system prepared in Example 1 ( Figure 2 a) and drug release curve ( Figure 2 b).
[0038] Figure 3 This is the hydrogen sulfide release curve under anaerobic conditions of the hydrogen sulfide precision delivery system prepared in Example 1.
[0039] Figure 4 This is the cytotoxicity experimental graph of the hydrogen sulfide precision delivery system prepared in Example 1.
[0040] Figure 5 This is an imaging picture of mice after the hydrogen sulfide precision delivery system was injected through the tail vein in Example 1, using transplanted breast cancer tumor mice as a model.
[0041] Figure 6 In Example 1, using transplanted breast cancer tumor mice as a model, the changes in the vascular structure, blood perfusion and hypoxia state of the mouse tumor site after the hydrogen sulfide precision delivery system was injected through the tail vein.
[0042] Figure 7 In Example 1, mice bearing transplanted breast cancer tumors were used as a model to evaluate the sensitization effect of the hydrogen sulfide precision delivery system on chemotherapy by regulating tumor vascular normalization.
[0043] Figure 8 In Example 1, mice with transplanted breast cancer tumors were used as a model to evaluate the effect of the hydrogen sulfide precision delivery system on regulating tumor vascular normalization on the immune microenvironment. DETAILED DESCRIPTION
[0044] The present invention is described in detail below in conjunction with the accompanying drawings and specific embodiments. This embodiment is implemented based on the technical solution of the present invention, and provides a detailed implementation method and specific operation process, but the protection scope of the present invention is not limited to the following embodiments.
[0045] In the following examples and comparative examples, unless otherwise specified, raw materials or processing techniques are conventional commercially available raw materials or conventional processing techniques in the art.
[0046] Embodiment 1:
[0047] This embodiment provides a hydrogen sulfide precision delivery system, and the construction method thereof comprises the following steps:
[0048] (1) 2-nitroimidazole (0.34 g, 3.0 mmol) was dissolved in 5.0 mL of N,N-dimethylformamide, and then potassium carbonate (0.83 g, 6.0 mmol) and N-(tert-butoxycarbonyl-amino)-bromohexane (0.84 g, 3.0 mmol) were added, and stirred at 80° C. for 12 h; after the reaction, the mixture was extracted with distilled water and ethyl acetate, and the organic layer was collected, dried and evaporated to obtain 2-(2-nitro-1H-imidazole)hexylamine protected by a Boc group;
[0049] (2) 2-(2-nitro-1H-imidazole)hexylamine protected by the Boc group (0.32 g, 1.0 mmol) was dissolved in 4.0 mL of dichloromethane, and then 2.0 mL of trifluoroacetic acid was added and stirred at room temperature for 3 h to remove the Boc group; after completion, the solution was adjusted to alkaline (pH = 8) with saturated sodium bicarbonate, extracted with distilled water and ethyl acetate, and the organic layer was collected and dried and evaporated to obtain 2-(2-nitro-1H-imidazole)hexylamine;
[0050] (3) Dissolve hyaluronic acid (0.2 g, 0.5 mmol, 3000 Da) in 10 mL of distilled water, add 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.38 g, 2.0 mmol) and N-hydroxysuccinimide (0.23 g, 2.0 mmol), and stir for 0.5 h in an ice-water bath to activate the carboxyl groups on the hyaluronic acid; then add 2-(2-nitro-1H-imidazole)hexylamine (0.21 mg, 1.0 mmol) and stir at room temperature for 24 h; then dialyze in distilled water for 48 h, and then freeze-dry to obtain the hyaluronic acid-nitroimidazole delivery system, referred to as HA-NIH;
[0051] (4) 20 mg of hydrogen sulfide donor (ADT) was dispersed in 2 mL of dimethyl sulfoxide as the organic phase; the solution was dripped into 200 mL of a 1 mg / mL hyaluronic acid-nitroimidazole delivery system aqueous solution in a stirring state at a flow rate of 2 mL / h; the solution was then dripped into 8 mL of water in a stirring state at a flow rate of 4 mL / h and stirred at room temperature for 24 h; the solution was then dialyzed in distilled water and freeze-dried to obtain a hydrogen sulfide delivery system, referred to as ADT@HN.
[0052] The prepared hydrogen sulfide delivery system was subjected to the following performance tests:
[0053] (1) In vitro exploration of the hypoxia response performance of ADT@HN: Sodium dithionite (Na2S2O4) was used to simulate endogenous hypoxia reducing agents, and the hypoxia response and drug release were demonstrated by UV-vis and HPLC methods.
[0054] (2) Using transplanted 4T1 breast cancer tumor mice as a model, we explored the enrichment effect of ADT@HN in vivo. ADT@HN was intravenously administered (1-15 mg / Kg), and the distribution of ADT@HN in vivo and the enrichment of tumors were observed using imaging technology.
[0055] The results are as follows:
[0056] Figure 1 The TEM (a), DLS (b), Zeta potential (c), UV-vis (d), FT-IR (e), and stability (f) characterization spectra of ADT@HN. It can be seen from the figure that the prepared ADT@HN is a uniform spherical shape with a particle size of about 100nm and a surface charge of -16.2mV. After being stored in PBS phosphate buffer, RPMI 1640 medium, and RPMI 1640 medium containing 10% FBS fetal bovine serum for two weeks, there is no obvious change in the solution and particle size, which shows that ADT@HN has been successfully prepared, and it has the characteristics of small particle size, negative surface charge, and good stability.
[0057] Figure 2 The following are the UV absorption spectra (a) and drug release curves (b) of ADT@HN hypoxia response. Sodium dithionite (Na2S2O4) was used to simulate the endogenous hypoxia reductant, and the hypoxia response and drug release were demonstrated by UV-vis method and HPLC method. As can be seen from the figure, there is no obvious change in the absorption peak under normoxic conditions and no hydrogen sulfide donor is released. However, under hypoxic conditions, there is an obvious increase in absorption around 275nm, an obvious decrease in absorption around 325nm, and a significant release of hydrogen sulfide donors.
[0058] Figure 3This is the hydrogen sulfide release curve of ADT@HN under hypoxic conditions. Sodium dithionite (Na2S2O4) was used to simulate the endogenous hypoxic reductant, tri(2-carboxyethyl)phosphine (TCEP) was used to simulate the endogenous reductase, and the H2S release kinetics of the sample was detected by the methylene blue method. From the data in the figure, it can be seen that ADT@HN releases almost no hydrogen sulfide under normoxic conditions, but continuously and stably releases hydrogen sulfide under hypoxic conditions.
[0059] Figure 4 This is a cytotoxicity test of the hydrogen sulfide delivery system; the prepared hydrogen sulfide delivery system was tested for cytotoxicity using HUVEC (human umbilical vein endothelial cells) and 4T1 (breast cancer cells), and the hydrogen sulfide delivery system was incubated with HUVEC and 4T1 cells at a series of concentrations of 0-50 μg / mL for 12h and 24h, respectively. The cell viability was detected using a CCK-8 kit. From the data in the figure, it can be seen that the prepared ADT@HN has no obvious toxicity to cells.
[0060] Figure 5 This is an image of a mouse with a transplanted 4T1 breast cancer tumor as a model, after ADT@HN (based on an ADT-OH concentration of 5 mg / kg) was injected through the tail vein. The ICG fluorescent probe-labeled hydrogen sulfide delivery system (abbreviated as ICG@HN) was used for in vivo fluorescence imaging of the 4T1 mouse tumor model to observe its in vivo tumor enrichment and tissue distribution, with a simple ICG fluorescent probe as a comparison. From the data in the figure, it can be seen that the image signal of the mouse tumor site gradually increases over time, and the signal value of the tumor site changes more significantly than other organs, proving that ADT@HN is only activated at the tumor site.
[0061] Figure 6The model is based on transplanted 4T1 breast cancer tumor mice. After ADT@HN (based on ADT-OH concentration of 5 mg / kg) was injected through the tail vein, the changes in vascular structure (a), blood perfusion (b) and hypoxia (c) in the tumor site of the mice were evaluated. 4T1 tumor-bearing mice were randomly divided into three groups: control group (Control), hydrogen sulfide donor (ADT-OH) and hydrogen sulfide delivery system (ADT@HN). 100μL PBS, ADT-OH and ADT@HN (based on ADT-OH concentration of 5 mg / kg) were injected intravenously, and the changes in vascular structure, blood perfusion and hypoxia in the tumor site were evaluated by immunofluorescence staining. CD31, also known as platelet-endothelial cell adhesion molecule, is present in the tight junctions between platelets, neutrophils and endothelial cells. It is often used to prove the existence of endothelial cell tissue and evaluate the formation of tumor blood vessels. NG2 protein is one of the markers of perivascular cells and H-type osteoblast perivascular stromal cells. It is an important source of bone mesenchymal stem cells and is often used to evaluate the functionalization of the vascular system. Pimonidazole is a hypoxia marker. Figure 6 From the data in a, we can see that after the injection of the hydrogen sulfide delivery system, the tumor vascular system in the tumor site of the mouse became more evenly distributed and tended to be normalized. Figure 6 From the data in b, we can see that after the injection of the hydrogen sulfide delivery system, the blood perfusion volume in the tumor site of mice increased significantly. Figure 6 As can be seen from the data in c, hypoxia in the tumor site of mice was greatly alleviated.
[0062] Figure 7 The study used transplanted 4T1 breast cancer tumor mice as a model to evaluate the sensitization effect of hydrogen sulfide delivery system on chemotherapy by regulating tumor vascular normalization. Figure 7 a, Luc-4T1 tumor-bearing mice were randomly divided into six groups: (G1) Control, (G2) ADT-OH, (G3) ADT@HN, (G4) Dox, (G5) ADT-OH+Dox, and (G6) ADT@HN+Dox. 100 μL PBS, ADT-OH, and ADT@HN (based on ADT-OH concentration of 5 mg / kg) were injected intravenously on days 0 and 4, respectively; 100 μL Dox (4 mg / kg) was injected intravenously on days 3 and 7, respectively. Figure 7 The luciferase imaging results in b showed that the combination of ADT@HN and Dox could effectively inhibit the growth of 4T1 tumors. Figure 7 From the data in c, we can see that tumors regulated by the hydrogen sulfide delivery system can more effectively enrich the chemotherapy drug doxorubicin (Dox) at the tumor site, showing better drug efficacy.
[0063] Figure 8The study used transplanted 4T1 breast cancer tumor mice as a model to evaluate the effect of the hydrogen sulfide precision delivery system on regulating tumor vascular normalization and the immune microenvironment. Figure 8 a, 4T1 tumor-bearing mice were randomly divided into four groups: (G1) Control (PBS), (G2) HA-NIH (HN), (G3) ADT, (G4) ADT@HN. On days 0 and 4, 100 μL of PBS, HN, ADT-OH, and ADT@HN (based on ADT-OH concentration of 5 mg / kg) were injected intravenously. After the sixth day of treatment, the mouse tumors were collected, and tumor cells were extracted using a tumor tissue digestion kit. Macrophages were stained with immunofluorescent antibodies at 4°C (F4 / 80-PE-stained macrophages, CD86-FITC-stained M1 pro-inflammatory macrophages, CD206-APC-stained M2 anti-inflammatory macrophages), and quantitative detection and analysis were performed using flow cytometry. As can be seen from the data in the figure, the proportion of M1 pro-inflammatory macrophages increased significantly, and the proportion of M2 anti-inflammatory macrophages decreased significantly, indicating that the tumor regulated by the hydrogen sulfide delivery system can present a better immune microenvironment.
[0064] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.
Claims
1. A method for constructing a hydrogen sulfide delivery system, characterized in that: The steps include: S1, dissolving 2-nitroimidazole in N,N-dimethylformamide, then adding potassium carbonate and N-(tert-butoxycarbonyl-amino)-bromohexane to react to obtain 2-(2-nitro-1H-imidazole)hexylamine protected by a Boc group; S2, dissolving the 2-(2-nitro-1H-imidazole)hexylamine obtained in step S1 in dichloromethane, and then adding trifluoroacetic acid to react to remove the Boc group to obtain 2-(2-nitro-1H-imidazole)hexylamine; S3, adding 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide to the hyaluronic acid aqueous solution to react and activate the carboxyl groups on the hyaluronic acid, and then adding 2-(2-nitro-1H-imidazole)hexylamine obtained in step S2 to react and obtain a hyaluronic acid-nitroimidazole delivery system; S4, dispersing the hydrogen sulfide donor in dimethyl sulfoxide as an organic phase and dripping it into the stirred aqueous solution of the hyaluronic acid-nitroimidazole delivery system obtained in step S3, and then dripping it into stirred water to obtain a hydrogen sulfide delivery system.
2. The method for constructing a hydrogen sulfide delivery system according to claim 1, characterized in that: In step S1, the molar ratio of 2-nitroimidazole, potassium carbonate and N-(tert-butoxycarbonyl-amino)-bromohexane is 1:2:
1.
3. The method for constructing a hydrogen sulfide delivery system according to claim 1, characterized in that: In step S1, in the reaction, the reaction temperature is 80-85° C., and the reaction is stirred for 8-12 hours.
4. The method for constructing a hydrogen sulfide delivery system according to claim 1, characterized in that: In step S1 and step S2, the concentration of 2-(2-nitro-1H-imidazole)hexylamine in dichloromethane is 80 mg / mL, and the volume ratio of dichloromethane to trifluoroacetic acid is 2:
1.
5. The method for constructing a hydrogen sulfide delivery system according to claim 1, characterized in that: In step S1 and step S2, the reaction temperature is 20-25° C. and the reaction is stirred for 3-6 hours.
6. The method for constructing a hydrogen sulfide delivery system according to claim 1, characterized in that: In step S1, in step S3, the concentration of hyaluronic acid in the hyaluronic acid aqueous solution is 20 mg / mL; The molar ratio of hyaluronic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, N-hydroxysuccinimide, and 2-(2-nitro-1H-imidazole)hexylamine is 1:4:4:
2.
7. The method for constructing a hydrogen sulfide delivery system according to claim 1, characterized in that: In step S1, in step S3, the conditions for adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide to react are: stirring at 0-5° C. for 1-2 hours; The reaction conditions for adding 2-(2-nitro-1H-imidazole)hexylamine obtained in step S2 are: stirring at 20-25° C. for 12-24 hours.
8. The method for constructing a hydrogen sulfide delivery system according to claim 1, characterized in that: In step S4, the concentration of the hyaluronic acid-nitroimidazole delivery system aqueous solution is 1-25 mg / mL, the mass ratio of the hydrogen sulfide donor to the hyaluronic acid-nitroimidazole delivery system is 1:10, and the volume ratio of dimethyl sulfoxide to water is 1:4; The flow rate of dripping into the aqueous solution of the hyaluronic acid-nitroimidazole delivery system is 1-10 mL / h, and the flow rate of dripping into water is 4-6 mL / h, and stirring is performed at 20-25° C. for 12-24 hours.
9. A hydrogen sulfide delivery system, characterized in that: Obtained based on the construction method described in any one of claims 1-8.
10. Use of the hydrogen sulfide delivery system according to claim 9, characterized in that: The hydrogen sulfide delivery system is used for preparing drugs for regulating tumor vascular normalization.
